The US Food and Drug Administration approved a new indication for Eli Lilly’s formulation of tirzepatide to treat moderate to severe OSA in people with obesity.
The US Food and Drug Administration has approved the obesity treatment tirzepatide for treating moderate to severe obstructive sleep apnea in adults with obesity.
Excess weight is a major risk factor for OSA, in which the upper airways become blocked multiple times during sleep and obstruct breathing. The condition causes loud snoring, recurrent awakenings, and daytime sleepiness. It is also associated withThe new OSA approval was based on two phase 3, double-blind randomized controlled trials, SURMOUNT-OSA, in patients with obesity and moderate to severe OSA, conducted at 60 sites in nine countries.
Side effects of tirzepatide include nausea, diarrhea, vomiting, constipation, abdominal discomfort and pain, injection site reactions, fatigue, hypersensitivity reactions , burping, hair loss, and gastroesophageal reflux disease.publication of the SURMOUNT-OSA results, Sanjay R.
Sleep Apnoea Sleep Disturbance Abnormal Sleep Pattern Sleep Disorder Somnipathy Obstructive Sleep Apnea Obstructive Sleep Apnea Syndrome Obstructive Sleep Apnoea Obstructive Sleep Apnoea Syndrome Sleep Obesity Obese U.S. Food And Drug Administration United States Food And Drug Administration FDA Food And Drug Administration (FDA) Food And Drug Administration Adherence
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Weight Loss Drug Zepbound Approved to Treat Sleep ApneaThe FDA expanded the approval of weight loss drug Zepbound to treat obstructive sleep apnea in adults with obesity. This makes it the first drug treatment for the disorder, which affects about 39 million adults in the United States.
Read more »
New Drug Approved for Sleep ApneaThe FDA has approved Eli Lilly's obesity drug Zepbound (tirzepatide) to treat moderate to severe obstructive sleep apnea in adults with obesity.
Read more »
FDA Approves Weight Loss Drug Zepbound for Sleep ApneaThe FDA has granted approval to Zepbound, a popular weight loss medication, for the treatment of moderate to severe obstructive sleep apnea. This marks the first FDA-approved prescription drug specifically for adults with obstructive sleep apnea.
Read more »
FDA says Eli Lilly's weight loss drug Zepbound is no longer in shortageThe decision that will eventually bar compounding pharmacies from making unbranded versions of the injection.
Read more »
FDA approves weight loss drug Zepbound for sleep apneaBerkeley Lovelace Jr. is a health and medical reporter for NBC News. He covers the Food and Drug Administration, with a special focus on Covid vaccines, prescription drug pricing and health care. He previously covered the biotech and pharmaceutical industry with CNBC.
Read more »
FDA approves Eli Lilly's weight loss drug Zepbound for sleep apnea, expanding use in U.S.The agency’s decision expands the use of Zepbound and could potentially pave the way for Eli Lilly to gain broader insurance coverage for the treatment.
Read more »